
Carole A Bewley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8235787/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phylogenomic analysis of the diversity of graspetides and proteins involved in their biosynthesis. Biology Direct, 2022, 17, 7.	4.6	9
2	<i>C</i> ₃ -Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity. ACS Chemical Biology, 2022, 17, 1450-1459.	3.4	1
3	Vertirhodins A–F, C-Linked Pyrrolidine-Iminosugar-Containing Pyranonaphthoquinones from Streptomyces sp. B15-008. Organic Letters, 2021, 23, 682-686.	4.6	6
4	Structural Basis for a Dual Function ATP Grasp Ligase That Installs Single and Bicyclic ω-Ester Macrocycles in a New Multicore RiPP Natural Product. Journal of the American Chemical Society, 2021, 143, 8056-8068.	13.7	20
5	Genome-Guided Discovery of Natural Products through Multiplexed Low-Coverage Whole-Genome Sequencing of Soil Actinomycetes on Oxford Nanopore Flongle. MSystems, 2021, 6, e0102021.	3.8	6
6	Lentzeacins A-E, New Bacterial-Derived 2,5- and 2,6-Disubstituted Pyrazines from a BGC-Rich Soil Bacterium Lentzea sp. GA3-008. Molecules, 2021, 26, 7197.	3.8	0
7	Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	3
8	Synthesis of 9-Dechlorochrysophaentin A Enables Studies Revealing Bacterial Cell Wall Biosynthesis Inhibition Phenotype in B. subtilis. Journal of the American Chemical Society, 2020, 142, 16161-16166.	13.7	4
9	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction. Journal of Natural Products, 2020, 83, 1288-1294.	3.0	10
10	X-ray Crystallography and Unexpected Chiroptical Properties Reassign the Configuration of Haliclonadiamine. Journal of the American Chemical Society, 2020, 142, 2755-2759.	13.7	7
11	Antimicrobial Chrysophaentin Analogs Identified from Laboratory Cultures of the Marine Microalga <i>Chrysophaeum taylorii</i> . Journal of Natural Products, 2019, 82, 148-153.	3.0	14
12	Tapping into personalized chemistry. Nature Chemical Biology, 2018, 14, 108-109.	8.0	2
13	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity, 2018, 48, 500-513.e6.	14.3	66
14	Chemical and Biophysical Approaches for Complete Characterization of Lectin–Carbohydrate Interactions. Methods in Enzymology, 2018, 598, 3-35.	1.0	1
15	Insights from NMR Spectroscopy into the Conformational Properties of Manâ€9 and Its Recognition by Two HIV Binding Proteins. ChemBioChem, 2017, 18, 764-771.	2.6	18
16	Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations. Molecular Pharmaceutics, 2017, 14, 2681-2689.	4.6	7
17	A New Natural Product Analog of Blasticidin S Reveals Cellular Uptake Facilitated by the NorA Multidrug Transporter. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
18	Tulongicin, an Antibacterial Tri-Indole Alkaloid from a Deep-Water <i>Topsentia</i> sp. Sponge. Journal of Natural Products, 2017, 80, 2556-2560.	3.0	40

#	Article	IF	CITATIONS
19	Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses, 2016, 8, 296.	3.3	108
20	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	4.7	51
21	Polybrominated Diphenyl Ethers: Structure Determination and Trends in Antibacterial Activity. Journal of Natural Products, 2016, 79, 1872-1876.	3.0	31
22	Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry. Bioorganic and Medicinal Chemistry, 2016, 24, 1718-1728.	3.0	7
23	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
24	Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles. ACS Infectious Diseases, 2016, 2, 882-891.	3.8	20
25	Marine sponge alkaloids as a source of anti-bacterial adjuvants. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5863-5866.	2.2	27
26	Effective Isotope Labeling of Proteins in a Mammalian Expression System. Methods in Enzymology, 2015, 565, 289-307.	1.0	9
27	Glycopeptide Mimetics Recapitulate Highâ€Mannoseâ€Type Oligosaccharide Binding and Function. Angewandte Chemie - International Edition, 2015, 54, 5603-5608.	13.8	7
28	HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opinion on Therapeutic Targets, 2015, 19, 765-783.	3.4	34
29	Binding of HIV-1 gp41-Directed Neutralizing and Non-Neutralizing Fragment Antibody Binding Domain (Fab) and Single Chain Variable Fragment (ScFv) Antibodies to the Ectodomain of gp41 in the Pre-Hairpin and Six-Helix Bundle Conformations. PLoS ONE, 2014, 9, e104683.	2.5	7
30	Chrysophaentins are competitive inhibitors of FtsZ and inhibit Z-ring formation in live bacteria. Bioorganic and Medicinal Chemistry, 2013, 21, 5673-5678.	3.0	47
31	Characterizing Carbohydrate–Protein Interactions by Nuclear Magnetic Resonance Spectroscopy. Biopolymers, 2013, 99, 796-806.	2.4	17
32	Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16. Nature Structural and Molecular Biology, 2013, 20, 804-813.	8.2	257
33	Inhibition of Hepatitis C Virus by the Cyanobacterial Protein <i>Microcystis viridis</i> Lectin: Mechanistic Differences between the High-Mannose Specific Lectins MVL, CV-N, and GNA. Molecular Pharmaceutics, 2013, 10, 4590-4602.	4.6	43
34	Geographic Variability and Anti-Staphylococcal Activity of the Chrysophaentins and Their Synthetic Fragments. Marine Drugs, 2012, 10, 1103-1125.	4.6	18
35	Peptides from Second Extracellular Loop of C-C Chemokine Receptor Type 5 (CCR5) Inhibit Diverse Strains of HIV-1. Journal of Biological Chemistry, 2012, 287, 15076-15086.	3.4	24
36	Structure-Based Identification and Neutralization Mechanism of Tyrosine Sulfate Mimetics That Inhibit HIV-1 Entry. ACS Chemical Biology, 2011, 6, 1069-1077.	3.4	31

#	Article	IF	CITATIONS
37	Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. Journal of Biomolecular NMR, 2011, 50, 197-207.	2.8	18
38	Susceptibility and mode of binding of the Mycobacterium tuberculosis cysteinyl transferase mycothiol ligase to tRNA synthetase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2480-2483.	2.2	19
39	Solution Structure of the Monovalent Lectin Microvirin in Complex with Manα(1–2)Man Provides a Basis for Anti-HIV Activity with Low Toxicity. Journal of Biological Chemistry, 2011, 286, 20788-20796.	3.4	67
40	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PC9. Nature, 2011, 480, 336-343.	27.8	794
41	Motualevic acids and analogs: Synthesis and antimicrobial structure–activity relationships. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4108-4111.	2.2	9
42	Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41. PLoS Pathogens, 2010, 6, e1001182.	4.7	44
43	Chrysophaentins Aâ^'H, Antibacterial Bisdiarylbutene Macrocycles That Inhibit the Bacterial Cell Division Protein FtsZ. Journal of the American Chemical Society, 2010, 132, 9069-9077.	13.7	97
44	Dequalinium, a New Inhibitor of Mycobacterium tuberculosis Mycothiol Ligase Identified by High-Throughput Screening. Journal of Biomolecular Screening, 2009, 14, 643-652.	2.6	43
45	Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naÃ ⁻ ve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology, 2009, 393, 112-119.	2.4	22
46	Motualevic Acids Aâ^'F, Antimicrobial Acids from the Sponge <i>Siliquariaspongia</i> sp Organic Letters, 2009, 11, 1087-1090.	4.6	60
47	Unprecedented Glycosidase Activity at a Lectin Carbohydrate-Binding Site Exemplified by the Cyanobacterial Lectin MVL. Journal of the American Chemical Society, 2009, 131, 16500-16508.	13.7	17
48	Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. Bioorganic and Medicinal Chemistry, 2008, 16, 10113-10120.	3.0	31
49	Illuminating the switch in influenza viruses. Nature Biotechnology, 2008, 26, 60-62.	17.5	20
50	Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology, 2008, 377, 170-183.	2.4	50
51	Sequestering of the Prehairpin Intermediate of gp41 by Peptide N36 ^{Mut(e,g)} Potentiates the Human Immunodeficiency Virus Type 1 Neutralizing Activity of Monoclonal Antibodies Directed against the N-Terminal Helical Repeat of gp41. Journal of Virology, 2008, 82, 10032-10041.	3.4	29
52	A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains. Journal of Virology, 2007, 81, 12946-12953.	3.4	37
53	Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4. Science, 2007, 317, 1930-1934.	12.6	379
54	Synergistic Inhibition of HIV-1 Envelope-Mediated Membrane Fusion by Inhibitors Targeting the N and C-Terminal Heptad Repeats of gp41. Journal of Molecular Biology, 2006, 364, 283-289.	4.2	23

#	Article	IF	CITATIONS
55	Cloning, expression and rapid purification of active recombinant mycothiol ligase as B1 immunoglobulin binding domain of streptococcal protein G, glutathione-S-transferase and maltose binding protein fusion proteins in Mycobacterium smegmatis. Protein Expression and Purification, 2006, 50, 128-136.	1.3	12
56	Conformational Changes in HIV-1 gp41 in the Course of HIV-1 Envelope Glycoprotein-Mediated Fusion and Inactivationâ€. Biochemistry, 2005, 44, 12471-12479.	2.5	59
57	Differential Inhibition of HIV-1 and SIV Envelope-Mediated Cell Fusion by C34 Peptides Derived from the C-Terminal Heptad Repeat of gp41 from Diverse Strains of HIV-1, HIV-2, and SIV. Journal of Medicinal Chemistry, 2005, 48, 3036-3044.	6.4	29
58	Characterization and HIV-1 Fusion Inhibitory Properties of Monoclonal Fabs Obtained From a Human Non-immune Phage Library Selected Against Diverse Epitopes of the Ectodomain of HIV-1 gp41. Journal of Molecular Biology, 2005, 353, 945-951.	4.2	27
59	Inhibition of HIV-1 Envelope-Mediated Fusion by Synthetic Batzelladine Analogues. Journal of Natural Products, 2004, 67, 1319-1324.	3.0	47
60	Temperature-Dependent Intermediates in HIV-1 Envelope Glycoprotein-Mediated Fusion Revealed by Inhibitors that Target N- and C-Terminal Helical Regions of HIV-1 gp41. Biochemistry, 2004, 43, 8230-8233.	2.5	22
61	New Carbohydrate Specificity and HIV-1 Fusion Blocking Activity of the Cyanobacterial Protein MVL: NMR, ITC and Sedimentation Equilibrium Studies. Journal of Molecular Biology, 2004, 339, 901-914.	4.2	56
62	Crambescidin 826 and Dehydrocrambine A:  New Polycyclic Guanidine Alkaloids from the Marine Sponge Monanchora sp. that Inhibit HIV-1 Fusion. Journal of Natural Products, 2003, 66, 1490-1494.	3.0	95
63	Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion. Journal of Biological Chemistry, 2003, 278, 20278-20285.	3.4	94
64	Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41. Journal of Biological Chemistry, 2002, 277, 14238-14245.	3.4	125
65	Site-specific Discrimination by Cyanovirin-N for α-Linked Trisaccharides Comprising the Three Arms of Man8 and Man9. Journal of Molecular Biology, 2002, 322, 881-889.	4.2	65
66	The Potent Anti-HIV Protein Cyanovirin-N Contains Two Novel Carbohydrate Binding Sites That Selectively Bind to Man8D1D3 and Man9with Nanomolar Affinity:Â Implications for Binding to the HIV Envelope Protein gp120. Journal of the American Chemical Society, 2001, 123, 3892-3902.	13.7	131
67	Rapid Validation of the Overall Structure of an Internal Domain-Swapped Mutant of the Anti-HIV Protein Cyanovirin-N Using Residual Dipolar Couplings. Journal of the American Chemical Society, 2001, 123, 1014-1015.	13.7	25
68	Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex. Structure, 2001, 9, 931-940.	3.3	130
69	Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity. Journal of Biological Chemistry, 2001, 276, 29485-29489.	3.4	88
70	Determination of the Relative Orientation of the Two Halves of the Domain-Swapped Dimer of Cyanovirin-N in Solution Using Dipolar Couplings and Rigid Body Minimization. Journal of the American Chemical Society, 2000, 122, 6009-6016.	13.7	83
71	Impact of Residual Dipolar Couplings on the Accuracy of NMR Structures Determined from a Minimal Number of NOE Restraints. Journal of the American Chemical Society, 1999, 121, 6513-6514.	13.7	108
72	Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. Journal of Molecular Biology, 1999, 288, 403-412.	4.2	160

#	Article	IF	CITATIONS
73	MINOR GROOVE-BINDING ARCHITECTURAL PROTEINS: Structure, Function, and DNA Recognition. Annual Review of Biophysics and Biomolecular Structure, 1998, 27, 105-131.	18.3	233
74	Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nature Structural Biology, 1998, 5, 571-578.	9.7	249
75	Lithistid Sponges: Star Performers or Hosts to the Stars. Angewandte Chemie - International Edition, 1998, 37, 2162-2178.	13.8	181
76	The solution structure of an HMC-I(Y)–DNA complex defines a new architectural minor groove binding motif. Nature Structural Biology, 1997, 4, 657-665.	9.7	337
77	Design of an expression system for detecting folded protein domains and mapping macromolecular interactions by NMR. Protein Science, 1997, 6, 2359-2364.	7.6	142